Lipid nanoparticle delivery system for targeted liver treatment of hyperuricemia
A novel lipid nanoparticle delivery system targets liver cells to treat hyperuricemia by inserting a recombinant uricase gene using CRISPR technology. This approach aims to reduce uric acid buildup without triggering immune responses.
Overview
This innovative solution leverages lipid nanoparticles to deliver a recombinant ancestral uricase gene and CRISPR components directly to liver cells. The goal is to address hyperuricemia by promoting the expression of uricase within liver cells, enabling the oxidation of uric acid while avoiding immune system detection. This method potentially offers a more effective treatment for conditions like gout, which are caused by uric acid accumulation due to the natural absence of a functional uricase enzyme in humans.
Technical specifications
Key features:
- Lipid nanoparticles facilitate precise delivery of genetic material to liver cells.
- Incorporates a liver-specific promoter to ensure uricase gene expression specifically in liver tissues.
- Utilizes CRISPR technology for genomic insertion of the uricase gene at a safe-harbor locus (AAVS1) within the host genome.
- Localizes uricase protein to liver cell peroxisomes, where it effectively oxidizes uric acid without circulating in the bloodstream.
- Reduces potential immune responses and minimizes harmful byproducts such as hydrogen peroxide, thanks to peroxisomal catalase activity.
Technology readiness level
Currently at Technology Readiness Level 4, this solution has been validated in laboratory settings using uricase-knockout mouse models. The next steps involve transitioning to human cells and further validation to confirm efficacy and safety before clinical deployment.
About Georgia State University
Georgia State University is a comprehensive public research university in downtown Atlanta, serving a large and diverse student body with a rapidly growing research enterprise. An urban innovation district and co-located collaboration spaces link faculty and students with corporate partners for prototyping, user testing, and joint problem-solving. Shared core laboratories and campus computing resources support industry-sponsored work, while proximity to Fortune 500 headquarters, major hospital systems, and the CDC enables quick access to real-world testbeds. Research is backed by competitive federal funding from agencies such as NIH, NSF, and DoD. A dedicated technology transfer office streamlines IP, licensing, and startup formation to speed commercialization.
delivered to your inbox.